Different Limb Lengths in Gastric Bypass Surgery (SLIM)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04219787 |
Recruitment Status :
Active, not recruiting
First Posted : January 7, 2020
Last Update Posted : November 13, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Obesity, Morbid Diabetes Mellitus, Type 2 Hypertension Dyslipidemias Sleep Apnea | Procedure: Long BPL LRYGB Procedure: Short BPL LRYGB | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 800 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Swiss Multicenter Randomized Controlled Trial on Different Limb Lengths in Gastric Bypass Surgery |
Actual Study Start Date : | June 1, 2020 |
Estimated Primary Completion Date : | November 30, 2028 |
Estimated Study Completion Date : | November 30, 2028 |
Arm | Intervention/treatment |
---|---|
Experimental: Long Biliopancreatic Limb LRYGB
LRYGB with an 180 cm biliopancreatic limb (BPL) and an alimentary limb (AL) of 80 cm.
|
Procedure: Long BPL LRYGB
LRYGB with an 180 cm BPL and an AL of 80 cm.
Other Name: LBPL LRYGB |
Active Comparator: Short Biliopancreatic Limb LRYGB
Standard LRYGB with a 80 cm BPL and a 180 cm long AL.
|
Procedure: Short BPL LRYGB
The second group will receive a standard LRYGB with a 80 cm BPL and a 180 cm long AL.
Other Name: SBPL LRYGB |
- Primary endpoint [ Time Frame: From baseline to 5 years after surgery. ]Percent total weight loss (%TWL, superiority), while not leading to a larger nutritional de- ficiency rate (non-inferiority).
- Secondary endpoints [ Time Frame: From baseline to 5 years after surgery. ]Percent excess body mass index loss (%EBMIL), remission of comorbidities, complication rate/safety, and quality of life 1, 3, and 5 years after long and short BPL RYGB.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- informed consent as documented by signature
- patients with BMI of 35 kg/m2 or higher who comply with the regulatory rules for bariatric surgery in Switzerland
Exclusion Criteria:
- general contraindications to kind of surgery
- known or suspected non-compliance, drug or alcohol abuse
- inability to follow the procedures of the study, e.g. due to language problems, psychological disorders etc. of the participant
- participation in another study
- age < 18 years or > 65 years
- BMI > 60 kg/m2
- height < 145 cm
- CL length of < 180 cm as measured intraoperatively
- ASA physical status classification > III
- inflammatory bowel disease
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04219787
Switzerland | |
Clarunis University Center for Gastrointestinal and Liver Diseases | |
Basel, Switzerland |
Study Chair: | Marko Kraljevic, MD | Clarunis - Universitäres Bauchzentrum Basel | |
Study Chair: | Marco Bueter, MD, Professor | University Hospital Zurch |
Responsible Party: | Clarunis - Universitäres Bauchzentrum Basel |
ClinicalTrials.gov Identifier: | NCT04219787 |
Other Study ID Numbers: |
2019-02392 |
First Posted: | January 7, 2020 Key Record Dates |
Last Update Posted: | November 13, 2023 |
Last Verified: | November 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Roux-en-Y Gastric Bypass Biliopancreatic Limb Length |
Diabetes Mellitus, Type 2 Dyslipidemias Obesity, Morbid Diabetes Mellitus Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
Lipid Metabolism Disorders Obesity Overweight Overnutrition Nutrition Disorders Body Weight |